Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2343 June 2025

APPLICANT (stamp or sticker acceptable)			PATIENT NHI:	REFERRER Reg No:	
Reg No:			First Names:	First Names:	
			Surname:	Surname:	
Address:			DOB:	Address:	
			Address:		
er:				Fax Number:	
lib					
ns from	any		vals valid for 6 months.		
and and and and and	or	There is documentation core Patient has an ECOG perform Disease has relapsed Patient is amer without menstrue and Patient has not Patient comme and There is no evice Treatment to be used in core	confirming disease is hormone-receptor positive and HER2-negative erformance score of 0-2 psed or progressed during prior endocrine therapy menorrhoeic, either naturally or induced, with endocrine levels consistent with a postmenopausal or instrual-potential state not received prior systemic endocrine treatment for metastatic disease menored treatment with ribociclib in combination with an endocrine partner prior to 1 July 2024 evidence of progressive disease combination with an endocrine partner		
and and		Patient has experienced a c treatment discontinuation Treatment must be used in	grade 3 or 4 adverse reaction to palbociclib that cannot combination with an endocrine partner	ot be managed by dose reductions and requires	
Renewal					
pproval ons from sites(tid	any k box reatn	relevant practitioner. Approxes where appropriate) nent must be used in combiner.	vals valid for 12 months. nation with an endocrine partner		
	and	and and and and and and and and and are stress tick box	plication ons from any relevant practitioner. Approsites (tick boxes where appropriate) Patient has unresectable loand Patient has an ECOG perform and Patient has an ECOG perform without menstrate and Patient has not received primary and Patient has not received primary Patient has an active Special and Patient has an active Special and Patient has an active Special and Patient has experienced a great treatment discontinuation Treatment must be used in and There is no evidence of prosites (tick boxes where appropriate) Treatment must be used in combined Treatment must be used in combined	First Names: Surname: DOB: Address: Brain any relevant practitioner. Approvals valid for 6 months. sites(tick boxes where appropriate) Patient has unresectable locally advanced or metastatic breast cancer and Patient has an ECOG performance score of 0-2 Patient has an ECOG performance score of 0-2 Patient has an ECOG performance score of 0-2 Patient has not received prior systemic endocrine therapy or Patient has not received prior systemic endocrine treatment for meta and Patient has not received prior funded treatment with ribociclib in combination with an and There is no evidence of progressive disease and Patient has not received prior funded treatment with a CDK4/6 inhibitor Patient has an active Special Authority approval for palbociclib and Patient has experienced a grade 3 or 4 adverse reaction to palbociclib that cannot treatment discontinuation Treatment must be used in combination with an endocrine partner and There is no evidence of progressive disease since initiation of palbociclib pproval Number (if known): pproval Number (if known): pproval Number (if known): pproval Number (if known): pproval Treatment must be used in combination with an endocrine partner Treatment must be used in combination with an endocrine partner	

I confirm the above details are correct and that in signing this form I understand I may be audited.